Table 1.
Characteristics of breast cancer patients included in the study (N = 101) and treatment parameters.
| Characteristic | Category/Unit | N (%) |
|---|---|---|
| Age | Years | 50.9 (42.1-59.1)∗ |
| Type of surgery | Mastectomy | 48 (47.5) |
| Conservative surgery | 53 (52.5) | |
| Side of surgery | Left | 48 (47.5) |
| Right | 53 (52.5) | |
| Tumour type | Invasive lobular carcinoma | 2 (2.0) |
| Invasive ductal carcinoma | 96 (95.0) | |
| Other | 3 (3.0) | |
| Cancer grade | 1 | 1 (1.0) |
| 2 | 31 (30.7) | |
| 3 | 69 (68.3) | |
| Chemotherapy scheme | AC/EC/FAC/FEC with taxanes | 54 (53.5) |
| AC/EC/FAC/FEC without taxanes | 43 (42.6) | |
| Other | 4 (4.0) | |
| Anthracyclines | Yes | 99 (98.0) |
| Doxorubicin | 6 (6.0) | |
| Epirubicin | 93 (92.1) | |
| No | 2 (2.0) | |
| Anthracyclines cumulative dose | Doxorubicin, mg/m2 BSA | 342 (318-413)∗ |
| Epirubicin, mg/m2 BSA | 353 (294-522)∗ | |
| Taxanes | Yes | 58 (57.4) |
| Paclitaxel | 17 (16.7) | |
| Docetaxel | 41 (40.6) | |
| No | 43 (42.6) | |
| Taxanes cumulative dose | Paclitaxel, mg/m2 BSA | 886 (739-938)∗ |
| Docetaxel, mg/m2 BSA | 286 (269-299)∗ | |
| Hormonal therapy | Yes | 57 (56.4) |
| No | 44 (43.6) | |
| Treatment scheme of RT | 25 × 2 Gy | 84 (83.2) |
| 17 or 18 × 2.5 Gy | 17 (16.8) | |
| Site of RT | Breast/mammary region | 58 (57.4) |
| (Breast/mammary region) + regional lymph nodes | 43 (42.6) | |
| RT technique | 2D RT | 80 (79.2) |
| 3D CRT | 14 (13.9) | |
| Electrons | 7 (6.9) | |
| Hypertension | Yes | 29 (28.7) |
| No | 72 (71.3) | |
| Hyperlipidemia | Yes | 21 (20.8) |
| No | 80 (79.2) | |
| Smoking | Yes | 16 (15.8) |
| No | 85 (84.2) | |
| Diabetes | Yes | 1 (1.0) |
| No | 100 (99.0) | |
| Body mass index | kg/m2 | 27.1 (24.3-29.7)∗ |
∗median (25%-75%). 2D RT: two-dimensional radiotherapy; 3D CRT: three-dimensional conformal radiotherapy; AC: doxorubicin, cyclophosphamide; BSA: body surface area calculated according to the Du Bois formula; EC: epirubicin, cyclophosphamide; FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC: 5-fluorouracil, epirubicin, and cyclophosphamide; Gy: Gray; RT: radiotherapy.